BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed AVLN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:b98a22ec10975f05ce3e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AVLN P2 readout (est.): AURA-IPF
DESCRIPTION:AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and
  Efficacy of AP02 (Nintedanib Solution) in IPF\nNCT07194382 | PHASE2 | REC
 RUITING | sponsor: Avalyn Pharma Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker AVLN (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT07194382\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07194382
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
